Clinical trials
Autologous Stem Cell Transplantation clinical trials
Below are recruiting autologous stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 215 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT05979363RecruitingPhase 2
CAR-T cell therapy for plasma cell leukemia patients
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
TianjinAges 18–75 - NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65 - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT07123545RecruitingPhase 1/Phase 2
Personalized T-cell therapy for advanced liver cancer
This trial tests a personalized treatment using your own immune cells (T-cells) trained to attack specific markers on your liver cancer. It is for people with advanced liver cancer that has worsened after at least two prior treatments and who have tumor tissue available for genetic testing.
Hangzhou, ZhejiangAges 18–75 - NCT06698484RecruitingPhase 2
CAR-T cell therapy for B-cell lymphoma that has returned or not responded
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
Bandar Tun Razak, Kuala LumpurAges 13–75 - NCT07523542RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Treatment-Resistant Lupus
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Shenzhen, GuangdongAges 18–70 - NCT07541391RecruitingPhase 1
CAR T-cell therapy for relapsed kappa myeloma
This trial tests a new treatment called CAR T-cells (your own immune cells engineered in the lab) designed to fight kappa-restricted multiple myeloma that has come back or stopped responding to standard drugs. The goal is to see if this treatment can help patients whose cancer has progressed despite previous therapies.
Melbourne, VictoriaAges 18 years+ - NCT05444712Recruiting
Stem cell transplant after best response in some T-cell lymphomas
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
AmiensAges 18–70 - NCT07389616RecruitingPhase 2/Phase 3
Preventing lymphoma return after transplant
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT05836896RecruitingPhase 1
Safety check of BCMA CAR T-cells made from your own immune cells
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
DresdenAges 18 years+ - NCT07382817RecruitingPhase 1
A study of CAR T cells for patients with certain T or NK cell cancers
This trial tests whether a new treatment, called CAR T cells that target CD94, can help people with specific types of T or NK cell lymphoma or leukemia that have not responded to other treatments or have come back. The goal is to see if it is safe and works against the cancer.
Houston, TexasAges 18 years+ - NCT05573802RecruitingPhase 1/Phase 2
Belantamab and other medicines for new multiple myeloma
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
AthensAges 18 years+ - NCT07126236RecruitingPhase 2
Epcoritamab for first relapse of large B-cell lymphoma
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Zaragoza, AragonAges 18 years+ - NCT07645469RecruitingPhase 1
WT1 T Cell Therapy With Azacitidine for AML Minimal Residual Disease
This trial tests a new type of immune therapy using your own T cells (white blood cells) that are trained to fight AML cancer cells. It's designed for patients whose AML has mostly gone away with chemotherapy but still has traces of cancer detectable in blood or bone marrow tests.
Seattle, WashingtonAges 18 years+ - NCT06140966RecruitingPhase 2
Daratumumab and Carfilzomib combo for high-risk multiple myeloma
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Wuhan, HubeiAges 18–70 - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years
Hear when a new Autologous Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autologous stem cell transplantation?
- Yes. Clin2 currently lists 215 recruiting autologous stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autologous stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autologous stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.